⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21004395 | 1.00 | — | — | |
| SCHEMBL21317517 | 1.00 | — | — | |
| SCHEMBL17433524 | 0.83 | BRD4 (0.36) | — | |
| SCHEMBL11622104 | 0.79 | KMT2A (0.32) | — | |
| SCHEMBL17433521 | 0.79 | BRD4 (0.41) | — | |
| SCHEMBL27068657 | 0.78 | KMT2A (0.31) | — | |
| SCHEMBL7812881 | 0.73 | CHRNB2 (0.33) | — | |
| SCHEMBL12930166 | 0.73 | BRD4 (0.37) | — | |
| SCHEMBL146924 | 0.72 | — | — | |
| SCHEMBL6715928 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512863-B1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | ATEA PHARMACEUTICALS INC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3865136-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR CORONA VIRUS TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-9828410-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160257706-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2014206349-A1 | OXA-THIA-BICYCLO[3.2.1]OCTANE DERIVATIVE, PREPARATION METHOD, AND USE OF SAME | 四川海思科制药有限公司 (CN) | 2014-12-31 | — | — | WO | disclosed |
| US-20140243339-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2011-05-05 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7446210-B2 | Factor Xa compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |